About PneumRx
News
PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction Coil (RePneu LVRC) System
May 15, 2012 - PneumRx today announced that it has received FDA approval to commence a 30-site pivotal clinical trial to support a PMA application for the RePneu LVRC.
PneumRx, Inc. Raises $33 Million in Capital
January 4, 2011 - Funds will be used to support European sales of the PneumRx RePneu Lung Volume Reduction Coil (LVRC) System and to conduct a Pivotal Clinical Trial to support a PMA Application.
PneumRx Gets CE Mark for Lung Volume Reduction Coil System
PneumRx has received CE Marking for its RePneu Lung Volume Reduction Coil System to treat late stage emphysema. The device is designed to implant coils into the lungs to compress damaged tissue and restore elasticity in healthier lung tissue. The system is a minimally invasive alternative to surgery, according to the company. PneumRx intends to launch the product in Europe later this year.
© Copyright 2010 PneumRx. All rights reserved.